Results of nimotuzumab and vinorelbine, radiation, and re-irradiation for diffuse pontine glioma in childhood.

Massimino, Maura; Biassoni, Veronica; Miceli, Rosalba; Schiavello, Elisabetta; Warmuth, M.; Modena, Piergiorgio; Casanova, Michela; Pecori, Emilia; Giangaspero, Felice; Antonelli, Manila; Buttarelli, Francesca Romana; Spreafico, Filippo; Pollo, Bianca; Anichini, Andrea; Podda, Marta; Sardi, Iacopo; Cecco, Loris De; Bode, Udo; Bach, F.; Gandola, Lorenza

doi:10.1200/jco.2014.32.15_suppl.10020

Cited by 12 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DIPG comprise a group of tumors with a generally bad prognosis despite initial response to irradiation, which is the ideal and accepted treatment for those tumors, with a median survival of one year. [1][2][3][4][7][8][9][10][11]17 Neither Chemotherapy or hypofractionation [12][13][14][15][16][17][18] nor irradiation dose escalation have improve survival, but increase toxicity.…”

Section: Discussionmentioning

confidence: 99%

“…The brainstem is defined as the pons, midbrain and medulla oblongata, and 70% to 80% of the tumors in this localization are diffuse intrinsic pontine gliomas (DIPG). They typically present short duration of symptoms (multiple bilateral cranial nerve deficits, specially VI and VII, and also ataxia) and characteristic appearance in imaging finding: histological confirmation has not been required; [1][2][3][4] there has been discussion about the histological diagnosis by biopsy. 5,6 Radiation therapy (RT) has remained the standard treatment with a low degree of efficacy and short term responses, generally with a 1 or 2 year median overall survival.…”

Section: Introductionmentioning

confidence: 99%

“…5,6 Radiation therapy (RT) has remained the standard treatment with a low degree of efficacy and short term responses, generally with a 1 or 2 year median overall survival. 1,3,[7][8][9][10][11] It have been attempted different strategies in order to improve the prognosis, which included the association of chemotherapy and also hypofractionation [12][13][14][15][16][17][18][19] but they not improved survival, and recent biologic drugs are combined with RT. 2,14,20,-23 We tested the hypothesis that the combination of RT with Nimotuzumab, a humanized monoclonal antibody (MAb) developed at the Center of Molecular Immunology, in Havana, Cuba, can improve the survival in DIPG.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Long term survival in diffuse infiltrative brainstem gliomas in children and adolescents treated with radiotherapy and Nimotuzumab

Alert¹,

Chon²,

Valdés³

et al. 2018

IJRRT

View full text Add to dashboard Cite

Background: Brainstem gliomas have a short survival time; chemotherapy has not improved outcome. We report the result obtained with the combination of Radiotherapy and the monoclonal antibody Nimotuzumab in a series of these tumors. Material and methods: 40 children and adolescents treated with irradiation and Nimotuzumab were included between Jan 2009 and December 2015, all with the diagnosis of diffuse infiltrative pontine gliomas (DIPG), irradiated at the Instituto Nacional de Oncologia y Radiobiologia, in Havana, Cuba. Nimotuzumab was applied during the period receiving Radiotherapy and them monthly for one year or more. Results: Median age at diagnosis was 7,9 years (range 3-18 years old); median survival was 18,4 months and Kaplan Meier survival was 42,5% at 2 years and 34,5% at 5 years, established till 9 years. Addition of Nimotuzumab was safe and well tolerated. Conclusion: Combination of Nimotuzumab and Radiotherapy is safe and could increase survival

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long term survival in diffuse infiltrative brainstem gliomas in children and adolescents treated with radiotherapy and Nimotuzumab

Alert¹,

Chon²,

Valdés³

et al. 2018

IJRRT

View full text Add to dashboard Cite

show abstract

“…Nimotuzumab is a humanized monoclonal antibody against EGFR, blocking binding to its ligands. Clinical studies have shown encouraging results in children with HGG and DIPG, although these will need further confirmation. Different EGFR inhibitors (Supporting Information Table S1), such as depatuxizumab mafodotin (NCT02343406), an antibody‐drug conjugate; apatinib (NCT02848794), a tyrosine‐kinase inhibitor; as well as ErbB‐pathway inhibitors, such as afatinib (NCT02372006), are currently being evaluated in clinical trials.…”

Section: Biology Of Phgg and Molecularly Directed Therapiesmentioning

confidence: 99%

Challenging the indiscriminate use of temozolomide in pediatric high‐grade gliomas: A review of past, current, and emerging therapies

Guerra‐García

Marshall

Cockle

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Pediatric high‐grade gliomas (pHGG) constitute 8% to 12% of primary brain tumors in childhood. The most widely utilized treatment encompasses surgical resection followed by focal radiotherapy and temozolomide. However, experiences over past decades have not demonstrated improved outcomes. pHGG have been classified into different molecular subgroups defined by mutations in histone 3, IDH gene, MAPK pathway, and others, thereby providing a rationale for various targeted therapies. Additionally, immunotherapy and drug repurposing have also become attractive adjunctive treatments. This review focuses on past, present, and emerging treatments for pHGG integrating molecular research with the mainstream pediatric drug development in Europe and the United States to sketch a way forward in the development of novel therapeutic approaches. The implementation of randomized clinical trials with adaptive designs, underpinned by a robust biological rationale, and harnessing collaboration between the pharmaceutical industry, academia, regulators and patients/parents organizations will be essential to improve the outcomes for these children.

show abstract

“…It has been shown to provide benefit in head and neck cancer[33], and is used in India. Other clinical trial data suggest a benefit in some pediatric patients with diffuse pontine gliomas[34]. …”

Section: Signaling Disruptionmentioning

confidence: 99%

Mechanisms of action of therapeutic antibodies for cancer

Redman

Hill

Aldeghaither

et al. 2015

Molecular Immunology

142

View full text Add to dashboard Cite

The therapeutic utility of antibodies and their derivatives is achieved by various means. The FDA has approved several targeted antibodies that disrupt signaling of various growth factor receptors for the treatment of a number of cancers. Rituximab, and other anti-CD20 monoclonal antibodies are active in B cell malignancies. As more experience has been gained with anti-CD20 monoclonal antibodies, the multifactorial nature of their anti-tumor mechanisms has emerged. Other targeted antibodies function to dampen inhibitory checkpoints. These checkpoint inhibitors have recently achieved dramatic results in several cancers, including melanoma. These and related antibodies continue to be investigated in the clinical and pre-clinical settings. Novel antibody structures that target two or more antigens have also made their way into clinical use. Tumor targeted antibodies can also be conjugated to chemo- or radiotherapeutic agents, or catalytic toxins, as a means to deliver toxic payloads to cancer cells. Here we provide a review of these mechanisms and a discussion of their relevance to current and future clinical applications.

show abstract

Results of nimotuzumab and vinorelbine, radiation, and re-irradiation for diffuse pontine glioma in childhood.

Cited by 12 publications

References 0 publications

Long term survival in diffuse infiltrative brainstem gliomas in children and adolescents treated with radiotherapy and Nimotuzumab

Long term survival in diffuse infiltrative brainstem gliomas in children and adolescents treated with radiotherapy and Nimotuzumab

Challenging the indiscriminate use of temozolomide in pediatric high‐grade gliomas: A review of past, current, and emerging therapies

Mechanisms of action of therapeutic antibodies for cancer

Contact Info

Product

Resources

About